Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 837 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support... September 21, 2020 Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term... September 15, 2023 ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step... July 4, 2025 Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with... November 22, 2024 Load more HOT NEWS FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and... “Supporting research is mission critical for me and always will be”... EMA Recommends Extension of Therapeutic Indications for Selpercatinib El cáncer en mi comunidad: Superar los retrasos en la atención...
